During the last session, ProKidney Corp (NASDAQ:PROK)’s traded shares were 0.37 million, with the beta value of the company hitting 1.33. At the end of the trading day, the stock’s price was $1.69, reflecting an intraday loss of -2.87% or -$0.05. The 52-week high for the PROK share is $4.44, that puts it down -162.72 from that peak though still a striking 30.18% gain since the share price plummeted to a 52-week low of $1.18. The company’s market capitalization is $492.99M, and the average intraday trading volume over the past 10 days was 0.48 million shares, and the average trade volume was 683.24K shares over the past three months.
ProKidney Corp (PROK) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. PROK has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ProKidney Corp (NASDAQ:PROK) trade information
ProKidney Corp (PROK) registered a -2.87% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.87% in intraday trading to $1.69, hitting a weekly high. The stock’s 5-day price performance is -0.29%, and it has moved by -2.03% in 30 days. Based on these gigs, the overall price performance for the year is -5.59%. The short interest in ProKidney Corp (NASDAQ:PROK) is 10.34 million shares and it means that shorts have 24.49 day(s) to cover.
The consensus price target of analysts on Wall Street is $5, which implies an increase of 66.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $6 respectively. As a result, PROK is trading at a discount of -255.03% off the target high and -77.51% off the low.
ProKidney Corp (PROK) estimates and forecasts
Statistics show that ProKidney Corp has underperformed its competitors in share price, compared to the industry in which it operates. ProKidney Corp (PROK) shares have gone down -49.85% during the last six months, with a year-to-date growth rate less than the industry average at 5.26% against 16.60.
While earnings are projected to return 0.28% in 2024.
PROK Dividends
ProKidney Corp is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
ProKidney Corp (NASDAQ:PROK)’s Major holders
ProKidney Corp insiders own 27.44% of total outstanding shares while institutional holders control 43.59%, with the float percentage being 60.07%.
Also, the Mutual Funds coming in first place with the largest holdings of ProKidney Corp (PROK) shares are Vanguard Total Stock Market Index Fund and Morgan Stanley Inst Fd Inc-Growth Port . Data provided on Jun 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 2.97 shares. This amounts to just over 2.32 percent of the company’s overall shares, with a $5.02 million market value. The same data shows that the other fund manager holds slightly less at 2.92, or about 2.28% of the stock, which is worth about $4.94 million.
